CA-ESRI
Esri , the global leader in location intelligence, today announced it is releasing for the first time ever a new high-resolution, 2020 global land cover map as part of the company’s Living Atlas . The map was built using European Space Agency (ESA) Sentinel-2 satellite imagery, and developed using a new machine learning workflow teaming with new Esri Silver Partner Impact Observatory , as well as long-time partner Microsoft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005176/en/
The new map will be updated annually supporting change detection and highlighting planetary land changes, especially related to the effects of human activity. A consistent map of land cover for the entire world based on the most current satellite information, the 2020 Global Land Cover Map can be combined with other data layers for green infrastructure, sustainability projects, and other conservation efforts that require a holistic picture of both the human and natural footprint on the planet. Later this year, Esri and Impact Observatory will make this new land cover model available to support on-demand land cover classification, allowing the GIS community to create maps for project areas as often as every week.
"This is a critical year for climate action," said Jack Dangermond, Esri founder and president. "With the UN Climate Change Conference of the Parties (COP26) bringing international parties together to address a set of common goals, we are happy to do our part in making this map available to users that are working towards the health of our planet."
Users will also be able to manipulate the map in association with other GIS layers such as terrain, hydrology, and more, all available in ArcGIS Living Atlas of the World, the foremost collection of geographic information from around the globe, including maps, apps, and data layers. Through the visualizations being released, planners worldwide will better understand the geography around them to make more informed decisions—enabling them to gain insight into locations with distinctive land cover, as well as human activity affecting them.
High-resolution, open, accurate, comparable, and timely land cover maps are critical for decision-makers in many industry sectors and developing nations. These maps improve understanding of important topics such as food security, land use planning, hydrology modeling, and resource management planning. In addition, national government resource agencies use land cover as a basis for understanding trends in natural capital, which helps define land planning priorities and is the basis of budget allocations.
Impact Observatory, contracted by Esri, developed a deep learning AI land classification model using a massive training dataset of billions of human-labeled image pixels, and applied this model to the Sentinel-2 2020 scene collection, processing over 400,000 Earth observations to produce the map. The unique machine learning approach used to create this global map will soon be available on demand, supporting land managers who need to monitor change in a specific area of interest, looking at annual change and seasonal differences in land cover.
"Global efforts are urging world leaders to set and achieve ambitious conservation targets," said Steve Brumby, Impact Observatory co-founder and CEO. "With support from the geospatial experts at Esri, and access to incredible compute resources at Microsoft, we were able to build in record time a land cover map that provides leaders in governments, NGOs, and across industries with a novel, timely view of the planet, and a new AI-powered capability for actionable, science-based insights on demand. In doing so, Impact Observatory hopes to contribute towards the global conservation effort."
Esri is releasing this valuable resource under a Creative Commons license to encourage broad adoption and ensure equitable access for planners creating a more sustainable planet. This content will be made available in ArcGIS Online as a map service and be freely available for use by its 10 million users. It will also be available for download and viewing. To explore the new 2020 Global Land Cover Map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory is a mission-driven technology company bringing artificial intelligence (AI) powered algorithms and on-demand data to sustainability and environmental risk analysis for governments, non-profit organizations, companies, and markets. Founded in 2020 in Washington, DC, Impact Observatory’s goal is to empower global decision-makers to be planetary superheroes, with the timely, actionable science-based insights they need to succeed. Visit us at impactobservatory.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005176/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom